Navigation Links
Roka Bioscience Completes $20 Million Series C Financing

WARREN, N.J., July 28, 2011 /PRNewswire/ -- Roka Bioscience, Inc. announced today that it recently completed a Series C round of equity financing, raising $20 million in new capital. The financing brings the total amount raised to $57.2 million since the company's formation in September 2009. The investor syndicate included participation from all existing investors including OrbiMed Advisors, New Enterprise Associates, Inc., TPG Biotech and Gen-Probe Incorporated (NASDAQ: GPRO).

"We are very pleased with the continued support of our existing investors and their confidence in our ability to become a leader in providing innovative solutions based on molecular technologies for the industrial markets," said Paul Thomas, CEO and President of Roka Bioscience. "We are on track to commercialize our first molecular assay for food safety testing later this year," he added.

Roka Bioscience was established in September 2009 through a spin-off of Gen-Probe's industrial testing assets and technology into a new independent company focused on developing rapid, highly accurate molecular assays for food safety testing and other industrial applications. Roka's nucleic acid tests will be based on proven technologies and instrument platforms with exclusive licensing rights from Gen-Probe. Eighteen former Gen-Probe employees with expertise in industrial fields joined Roka at the time of the spin-off. Today the company has 75 employees.

"Combining a proven technology platform with an experienced management team and a large market opportunity is a recipe for success. We believe Roka has all three," said Jonathan Silverstein, General Partner, OrbiMed Advisors.

About Roka Bioscience

Roka Bioscience is a privately held company focused on developing and commercializing innovative solutions based on molecular technologies for the industrial markets. The company's scientific platform is based on proven, proprietary technologies used widely in clinical diagnostic testing and now being introduced into food safety and other industrial markets. Roka's current product line provides food safety professionals with a fully-automated molecular pathogen detection solution that delivers rapid, accurate results and improved laboratory efficiencies. For more information, visit

Steve Sobieski, Chief Financial Officer
(908) 605-4621

SOURCE Roka Bioscience
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... a legally blind and certified personal trainer is helping to develop a weight loss fitness ... to fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
Breaking Medicine News(10 mins):